Research programme: anti-cancer immunotherapies - Nouscom

Drug Profile

Research programme: anti-cancer immunotherapies - Nouscom

Alternative Names: Neoantigen vaccines; NOUS 100 PV; NOUS 209; NOUS THV 001; Oncolytic antigenless vaccines

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nouscom
  • Class Antineoplastics; Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Nov 2017 Preclinical data for Cancer released by NousCom
  • 09 Nov 2017 Preclinical trials in Cancer in Switzerland (unspecified route), before November 2017 (Nouscom pipeline, November 2017)
  • 06 Nov 2017 NousCom plans a phase I/II trial of NOUS 209 for Cancer in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top